Page 138 - 2020年1月第31卷第2期

cohort study[J]. JAMA Oncol，2016，2（10）：1317-1325. echocardiography and biomarkers for the extended predic-
[25] CAMERON D，PICCART-GEBHART MJ，GELBER RD， tion of cardiotoxicity in patients treated with anthracy-
et al. 11 years’follow-up of trastuzumab after adjuvant clines，taxanes，and trastuzumab[J]. Circ Cardiovasc Ima-
chemotherapy in HER2-positive early breast cancer：final ging，2012，5（5）：596-603.
analysis of the HER ceptin adjuvant（HERA）trial[J]. Lan- [38] SKOVGAARD D，HASBAK P，KJAER A. BNP predicts
cet，2017，389（10075）：1195-1205. chemotherapy-related cardiotoxicity and death：compari-
[26] BOWLES EJ，WELLMAN R，FEIGELSON HS，et al. son with gated equilibrium radionuclide ventriculogra-
Risk of heart failure in breast cancer patients after anthra- phy[J]. PLoS One，2014. DOI：10.1371/journal.pone.
cycline and trastuzumab treatment：a retrospective cohort 0096736.
study[J]. J Natl Cancer Inst，2012，104（17）：1293-1305. [39] ABDEL-QADIR H，ONG G，FAZELZAD R，et al. Inter-
[27] TOUYZ RM，HERRMANN J. Cardiotoxicity with vascu- ventions for preventing cardiomyopathy due to anthracy-
lar endothelial growth factor inhibitor therapy[J]. NPJ Pre- clines：a Bayesian network meta-analysis[J]. Ann Oncol，
cis Oncol，2018. DOI：10.1038/s41698-018-0056-z. 2017，28（3）：628-633.
[28] KENIGSBERG B，WELLSTEIN A，BARAC A. Left ven- [40] AVILA MS，AYUB-FERREIRA SM，DE BARROS WAN-
tricular dysfunction in cancer treatment：is it relevant? [J]. DERLEY MR JR，et al. Carvedilol for prevention of che-
JACC Heart Fail，2018，6（2）：87-95. motherapy-related cardiotoxicity：the CECCY trial[J]. J
[29] ABDEL-RAHMAN O. 5-fluorouracil-related cardiotoxici- Am Coll Cardiol，2018，71（20）：2281-2290.
ty；findings from five randomized studies of 5-fluoroura- [41] Clinical Trials. Preventing anthracycline cardiovascular
cil-based regimens in metastatic colorectal cancer[J]. Clin toxicity with statins：PREVENT[EB/OL].（2018-08-31）
Colorectal Cancer，2019，18（1）：58-63. [2019-01-18]. https：//clinicaltrials.gov/ct2/show/NCT019-
[30] GRONICH N，LAVI I，BARNETT-GRINESS O，et al. Ty- 88571.
rosine kinase-targeting drugs-associated heart failure[J]. [42] VAN DALEN EC，CARON HN，DICKINSON HO，et al.
Br J Cancer，2017，116（10）：1366-1273. Cardioprotective interventions for cancer patients recei-
[31] NARAYAN V，KEEFE S，HAAS N，et al. Prospective ving anthracyclines[J]. Cochrane Database Syst Rev，
evaluation of sunitinib-induced cardiotoxicity in patients 2011. DOI：10.1002/14651858.CD003917.
with metastatic renal cell carcinoma[J]. Clin Cancer Res， [43] PITUSKIN E，MACKEY JR，KOSHMAN S，et al. Multi-
2017，23（14）：3601-3609. disciplinary approach to novel therapies in cardio-oncolo-
[32] ARMENIAN SH，LACCHETTI C，BARAC A，et al. Pre- gy research（MANTICORE 101-breast）：a randomized
vention and monitoring of cardiac dysfunction in survi- trial for the prevention of trastuzumab-associated cardio-
vors of adult cancers：American Society of Clinical Oncol- toxicity[J]. J Clin Oncol，2016，35（8）：870-877.
ogy clinical practice guideline[J]. J Clin Oncol，2017，35 [44] BOEKHOUT AH，GIETEMA JA，MILOJKOVIC KERK-
（8）：893-911. LAAN B，et al. Angiotensin Ⅱ -receptor inhibition with
[33] VIRANI SA，DENT S，BREZDEN-MASLEY C，et al. Ca- candesartan to prevent trastuzumab-related cardiotoxic ef-
nadian Cardiovascular Society guidelines for evaluation fects in patients with early breast cancer：a randomized
and management of cardiovascular complications of can- clinical trial[J]. JAMA Oncol，2016，2（8）：1030-1037.
cer therapy[J]. Can J Cardiol，2016，32（7）：831-841. [45] GUGLIN M，KRISCHER J，TAMURA R，et al. Rando-
[34] PLANA JC，GALDERISI M，BARAC A，et al. Expert con- mized trial of lisinopril versus carvedilol to prevent tras-
sensus for multimodality imaging evaluation of adult pa- tuzumab cardiotoxicity in patients with breast cancer[J]. J
tients during and after cancer therapy：a report from the Am Coll Cardiol，2019，73（22）：2859-2868.
American Society of Echocardiography and the European [46] CARDINALE D，COLOMBO A，LAMANTIA G，et al.
Association of Cardiovascular Imaging[J]. J Am Soc Echo- Anthracycline-induced cardiomyopathy：clinical relevance
cardiogr，2014，27（9）：911-939. and response to pharmacologic therapy[J]. J Am Coll Car-
[35] 汪羚利，陈少敏，李昭屏.超声心动图评价抗肿瘤药物心 diol，2010，55（3）：213-220.
脏毒性的研究进展[J].心血管病学进展，2016，37（5）： [47] THAKUR A，WITTELES RM. Cancer therapy-induced
516-521. left ventricular dysfunction：interventions and progno-
[36] SMISETH OA，TORP H，OPDAHL A，et al. Myocardial sis[J]. J Card Fail，2014，20（3）：155-158.
strain imaging：how useful is it in clinical decision mak- （收稿日期：2019-01-25 修回日期：2019-10-15）
ing?[J]. Eur Heart J，2015，37（15）：1196-1207. （编辑：张元媛）
[37] SAWAYA H，SEBAG IA，PLANA JC，et al. Assessment of

·256 · China Pharmacy 2020 Vol. 31 No. 2 中国药房 2020年第31卷第2期